The genomics of new drugs in sickle cell disease

Pharmacogenomics

Volumn 7, Issue 6, 2006, Pages 909-917

  Makis, Alexandros C ^a   Hatzimichael, Eleftheria C ^a   Stebbing, Justin ^b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Phenotype; Sickle cell disease; Single nucleotide polymorphisms; Treatment

Indexed keywords

2,2 BIS(4 FLUOROPHENYL) 2 PHENYLACETAMIDE; 5 AZA 2' DEOXYCYTIDINE; ARGININE; AZACITIDINE; BUTYRIC ACID; CLOTRIMAZOLE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DNA METHYLTRANSFERASE INHIBITOR; FOLIC ACID; GARDOS CHANNEL BLOCKING AGENT; HEMOGLOBIN; HYDROXYUREA; IRON CHELATING AGENT; NITRIC OXIDE; PENICILLIN G; PNEUMOCOCCUS VACCINE; POLOXAMER; POTASSIUM CHANNEL BLOCKING AGENT; PYROGLUTAMATE MAGNESIUM; SALAZOSULFAPYRIDINE; SILDENAFIL; SURFACTANT; UNCLASSIFIED DRUG;

CANCER; CEREBROVASCULAR DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESPONSE; ERYTHROCYTE TRANSFUSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; INFECTION PREVENTION; LEUKEMIA; NONHUMAN; PHARMACOGENOMICS; PHENOTYPE; QUALITY OF LIFE; REVIEW; SECOND CANCER; SICKLE CELL ANEMIA; STREPTOCOCCUS INFECTION;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; AZACITIDINE; BUTYRATES; DRUG RESISTANCE; HUMANS; HYDROXYUREA; NITRIC OXIDE; PHARMACOGENETICS; PHENOTYPE; POLOXAMER; POLYMORPHISM, GENETIC; SULFASALAZINE; TOXICOGENETICS;

EID: 33749024141     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.7.6.909     Document Type: Review

References (86)

1. Schnog JB, Duits AJ, Muskiet FA et al.: Sickle cell disease; a general overview. Neth. J. Med. 62(10), 364-374 (2004).
2. Makis AC, Hatzimichael EC, Bourantas KL: The role of cytokines in sickle cell disease. Ann. Hematol. 79(8), 407-413 (2000).
3. Stuart MJ, Nagel RL: Sickle-cell disease. Lancet 364, 1343-1360 (2004) (9442).
4. Strasser BJ: Perspectives: molecular medicine. "Sickle cell anemia, a molecular disease". Science 286, 1488-1490 (1999) (5444).
5. Steinberg MH: Predicting clinical severity in sickle cell anemia. Br. J. Haematol. 129(4), 465-481 (2005).
6. Nagel RL, Bookchin RM, Johnson J et al.: Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc. Natl Acad. Sci USA 76(2), 670-672 (1979).
7. Watson RJ: The hereditary anemias. Bull. NY Acad. Med. 30(2), 106-121 (1954).
8. Conley CL, Weatherall DJ, Richardson SN et al.: Hereditary persistence of fetal hemoglobin: a study of 79 affected persons in 15 Negro families in Baltimore. Blood 21, 261-281 (1963).
9. Perrine RP, Pembrey ME, John P et al.: Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects. Ann. Intern. Med. 88(1), 1-6 (1978).
10. Elford HL: Effect of hydroxyurea on ribonucleotide reductase. Biochem. Biophys. Res. Commun. 33(1), 129-135 (1968).
11. Jordan A, Reichard P: Ribonucleotide reductases. Annu. Rev. Biochem. 67, 71-98 (1998).
12. Okpala IE: New therapies for sickle cell disease. Hematol. Oncol. Clin. North Am. 19(5), 975-87, ix (2005).
13. Steinberg MH, Barton F, Castro O et al.: Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289(13), 1645-1651 (2003).
14. de Montalembert M, Brousse V, Elie C et al.: Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica 91 (1), 125-128 (2006).
15. Scott JP, Hillery CA, Brown ER et al.: Hydroxyurea therapy in children severely affected with sickle cell disease. J. Pediatr. 128(6), 820-828 (1996).
16. Ferster A, Tahriri P, Vermylen C et al.: Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 97(11), 3628-3632 (2001).
17. Gulbis B, Haberman D, Dufour D et al.: Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood 105(7), 2685-2690 (2005).
18. Halsey C, Roberts IA: The role of hydroxyurea in sickle cell disease. Br. J. Haematol. 120(2), 177-186 (2003).
19. Wang WC, Wynn LW, Rogers ZR et al.: A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J. Pedriatr. 139(6), 790-796 (2001).
20. Ware RE, Zimmerman SA, Schultz WH: Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 94(9), 3022-3026 (1999).
21. Charache S, Terrin ML, Moore RD et al.: Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N. Engl. J. Med.. 332(20), 1317-1322 (1995).
22. Valafar H, Valafar F, Darvill A et al.: Predicting the effectiveness of hydroxyurea in individual sickle cell anemia patients. Artif. Intell. Med. 18(2), 133-148 (2000).
23. Thein SL, Sampietro M, Rohde K et al.: Detection of a major gene for heterocellular hereditary persistence of fetal hemoglobin after accounting for genetic modifiers. Am. J. Hum. Genet. 54(2), 214-228 (1994).
24. Chang YC, Smith KD, Moore RD et al.: An analysis of fetal hemoglobin variation in sickle cell disease: the relative contributions of the X-linked factor, β-globin haplotypes, α-globin gene number, gender, and age. Blood 85(4), 1111-1117 (1995).
25. Garner C, Mitchell J, Hatzis T et al.: Haplotype mapping of a major quantitative-trait locus for fetal hemoglobin production, on chromosome 6q23. Am. J. Hum. Genet. 62(6), 1468-1474 (1998).
26. Garner CP, Tatu T, Best S et al.: Evidence of genetic interaction between the β-globin complex and chromosome 8q in the expression of fetal hemoglobin. Am. J. Hum. Genet. 70(3), 793-799 (2002).
27. Wyszynski DF, Baldwin CT, Cleves MA et al.: Genetic polymorphisms associated with fetal hemoglobin response to hydroxyurea in patients with sickle cell anemia. Blood 104, 34a (2004).
28. Yen Y, Grill SP, Dutschman GE et al.: Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. Cancer Res. 54(14), 3686-3691 (1994).
29. Styles LA, Lubin B, Vichinsky E et al.: Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood 89(7), 2554-2559 (1997).
30. 2 production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood 99(7), 2297-2303 (2002).
31. Heeney MM, Howard TA, Zimmerman SA, Ware RE: UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia. J. Lab. Clin. Med. 141(4), 279-282 (2003).
32. Mavilio F, Giampaolo A, Care A et al.: Molecular mechanisms of human hemoglobin switching: selective undermethylation and expression of globin genes in embryonic, fetal and adult erythroblasts. Proc. Natl Acad. Sci USA 80(22), 6907-6911 (1983).
33. van der Ploeg LH, Flavell RA: DNA methylation in the human γδβ-globin locus in erythroid and nonerythroid tissues. Cell 19(4), 947-958 (1980).
34. Tagle DA, Koop BF, Goodman M et al.: Embryonic epsilon and γ-globin genes of a prosimian primate (Galago crassicaudatus). Nucleotide and amino acid sequences, developmental regulation and phylogenetic footprints. J. Mol. Biol. 203(2), 439-455 (1988).
35. DeSimone J, Heller P, Hall L, Zwiers D. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc. Natl Acad. Sci USA 79(14), 4428-4431 (1982).
36. Charache S, Dover G, Smith K et al.: Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the γδβ-globin gene complex. Proc. Natl Acad. Sci. USA 80(15), 4842-4846 (1983).
37. Ley TJ, DeSimone J, Noguchi CT et al.: 5-Azacytidine increases γ-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 62 (2), 370-380 (1983).
38. Carr BI, Reilly JG, Smith SS et al.: The tumorigenicity of 5-azacytidine in the male Fischer rat. Carcinogenesis 5(12), 1583-1590 (1984).
39. Sorm F, Vesely J: Effect of 5-aza-2′-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma 15(4), 339-343 (1968).
40. Vesely J, Cihak A, Sorm F: Characteristics of mouse leukemic cells resistant to 5-azacytidine and 5-aza-2′-deoxycytidine. Cancer Res. 28(10), 1995-2000 (1968).
41. Wijermans P, Lubbert M, Verhoef G et al.: Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter Phase II study in elderly patients. J. Clin. Oncol. 18(5), 956-962 (2000).
42. Lubbert M, Wijermans PW: Epigenetic therapy in MDS and acute AML: focus on decitabine. Ann. Hematol. 84(Suppl. 130), 1-2 (2005).
43. Koshy M, Dorn L, Bressler L et al. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 96(7), 2379-2384 (2000).
44. DeSimone J, Koshy M, Dorn L et al.: Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 99(11), 3905-3908 (2002).
45. Saunthararajah Y, Hillery CA, Lavelle D et al.: Effects of 5-aza-2-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 102(12), 3865-3870 (2003).
46. Schroder JK, Kirch C, Flasshove M et al.: Constitutive overexpression of the cytidine deaminase gene confers resistance to cytosine arabinoside in vitro. Leukemia 10(12), 1919-1924 (1996).
47. Schroder JK, Kirch C, Seeber S, Schutte J: Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia. Br. J. Haematol. 103(4), 1096-1103 (1998).
48. Yue L, Saikawa Y, Ota K et al.: A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 13(1), 29-38 (2003).
49. Shi JY, Shi ZZ, Zhang SJ et al.: Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 14(11), 759-768 (2004).
50. Rosen MB, Chernoff N. 5-Aza-2′-deoxycytidine-induced cytotoxicity and limb reduction defects in the mouse. Teratology 65(4), 180-190 (2002).
51. Atweh GF, Sutton M, Nassif I et al.: Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 93(6), 1790-1797 (1999).
52. Perrine SP, Ginder GD, Faller DV et al.: A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N. Engl. J. Med.. 328(2), 81-86 (1993).
53. Sher GD, Ginder GD, Little J et al.: Extended therapy with intravenous arginine butyrate in patients with β-hemoglobinopathies. N. Engl. J. Med.. 332(24), 1606-1610 (1995).
54. Dover GJ, Brusilow S, Charache S: Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 84(1), 339-343 (1994).
55. Weinberg RS, Ji X, Sutton M et al.: Butyrate increases the efficiency of translation of γ-globin mRNA: Blood 105(4), 1807-1809 (2005).
56. Pace BS, Qian XH, Sangerman J et al. p38 MAP kinase activation mediates γ-globin gene induction in erythroid progenitors. Exp. Hematol. 31(11), 1089-1096 (2003).
57. Wyszynski DF, Baldwin CT, Cleves MA et al.: Polymorphisms near a chromosome 6q QTL area are associated with modulation of fetal hemoglobin levels in sickle cell anemia. Cell. Mol. Biol. (Noisy -le-grand). 50(1), 23-33 (2004).
58. + channels by cytochrome P-450 inhibitors. J. Biol. Chem. 267(17), 11789-11793 (1992).
59. Brugnara C, Gee B, Armsby CC et al.: Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease. J. Clin. Invest. 97(5), 1227-1234 (1996).
60. + channel: the imidazole ring is not required for inhibitory activity. J. Pharmacol. Exp. Ther. 273(1), 266-272 (1995).
61. Stocker JW, de Franceschi L, McNaughton-Smith GA et al.: ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood 101(6), 2412-2418 (2003).
62. de Franceschi L, Bachir D, Galacteros F et al.: Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J. Clin. Invest. 100(7), 1847-1852 (1997).
63. de Franceschi L, Bachir D, Galacteros F et al.: Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease. Br. J. Haematol. 108(2), 284-289 (2000).
64. Brugnara C: Sickle cell disease: from membrane pathophysiology to novel therapies for prevention of erythrocyte dehydration. J. Pediatr. Hematol. Oncol. 25(12), 927-933 (2003).
65. Elion JE, Brun M, Odievre MH et al.: Vaso-occlusion in sickle cell anemia: role of interactions between blood cells and endothelium. Hematol. J. 5(Suppl 3), S195-S198 (2004).
66. Gladwin MT, Schechter AN, Ognibene FP et al.: Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation 107(2), 271-278 (2003).
67. Gladwin MT, Rodgers GP: Pathogenesis and treatment of acute chest syndrome of sickle-cell anemia. Lancet 355(9214), 1476-1478 (2000).
68. Kyle MA, Kato GJ: Sickle cell disease and nitric oxide: A paradigm shift? Int. J. Biochem. Cell Biol. 38, 1237-1243 (2006).
69. Reiter CD, Wang X, Tanus-Santos JE et al.: Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat. Med. 8(12), 1383-1389 (2002).
70. Morris CR: New strategies for the treatment of pulmonary hypertension in sickle cell disease: the rationale for arginine therapy. Treat. Respir. Med. 5(1), 31-45 (2006).
71. Weiner DL, Hibberd PL, Betit P et al.: Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA 289(9), 1136-1142 (2003).
72. Sharan K, Surrey S, Ballas S et al.: Association of T-786C eNOS gene polymorphism with increased susceptibility to acute chest syndrome in females with sickle cell disease. Br. J. Haematol. 124(2), 240-243 (2004).
73. Sullivan KJ, Kissoon N, Duckworth LJ et al.: Low exhaled nitric oxide and a polymorphism in the NOS I gene is associated with acute chest syndrome. Am. J. Respir. Crit. Care Med. 164(12), 2186-2190 (2001).
74. Nolan VG, Baldwin C, Ma Q et al.: Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anaemia. Br. J. Haematol. 128(2), 266-272 (2005).
75. Nakamura T, Saito Y, Ohyama Y et al.: Production of nitric oxide, but not prostacyclin, is reduced in klotho mice. Jpn. J. Pharmacol. 89(2), 149-156 (2002).
76. Kassim AA, Fabry ME, Nagel RL: Acute priapism associated with the use of sildenafil in a patient with sickle cell trait. Blood 95(5), 1878-1879 (2000).
77. Bialecki ES, Bridges KR: Sildenafil relieves priapism in patients with sickle cell disease. Am. J. Med. 113(3), 252 (2002).
78. Machado RF, Martyr S, Kato GJ et al.: Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br. J. Haematol. 130(3), 445-453 (2005).
79. Eisenhardt A, Sperling H, Hauck E et al.: ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction. Urology 62(1), 152-157 (2003).
80. Orringer EP, Casella JF, Ataga KI et al.: Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. JAMA 286(17), 2099-2106 (2001).
81. Ballas SK, Files B, Luchtman-Jones L et al.: Safety of purified poloxamer 188 in sickle cell disease: Phase I study of a nonionic surfactant in the management of acute chest syndrome. Hemoglobin 28(2), 85-102 (2004).
82. Grindel JM, Jaworski T, Piraner O et al.: Distribution, metabolism, and excretion of a novel surface-active agent, purified poloxamer 188, in rats, dogs, and humans. J. Pharm. Sci. 91(9), 1936-1947 (2002).
83. Solovey AA, Solovey AN, Harkness J, Hebbel RP: Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood 97(7), 1937-1941 (2001).
84. Kaul DK, Liu XD, Choong S et al.: Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am. J. Physiol. Heart Circ. Physiol. 287(1), H293-H301 (2004).
85. Kumagai S, Komada F, Kita T et al.: N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis. Pharm. Res. 21(2), 324-329 (2004).
86. Sabbagh N, Delaporte E, Marez D et al.: NAT2 genotyping and efficacy of sulfasalazine in patients with chronic discoid lupus erythematosus. Pharmacogenetics 7(2), 131-135 (1997).